BOTOX® Cosmetic (onabotulinumtoxina) Celebrates 10-year Anniversary Searching For "Women Just Like You" To Be Featured In An Advertisement In PEOPLE® Magazine

IRVINE, Calif., April 19, 2012 /PRNewswire/ -- Ten years ago, BOTOX® Cosmetic (onabotulinumtoxinA) was approved by the United States Food and Drug Administration (FDA) to temporarily improve the look of moderate to severe frown lines between the eyebrows in people ages 18-65.  In celebration of the millions of women who have been treated with BOTOX® Cosmetic over the past decade, BOTOX® Cosmetic and PEOPLE® magazine, in a marketing campaign, are searching for "Women Just Like You" who put their best face forward every day at work, at home and in their community.

Women are invited to go to www.WomenJustLikeYou.com to share their – or their friend's – personal story about the inspiring things they do for the people in their lives or in their communities, such as how they:

• Help improve the health of themselves or others;
• Do a job that makes an impact on their industry or in their community;
• Support a cause or make a contribution to their own community; or
• Promote healthy relationships with others or on behalf of others. 

"The 'Women Just Like You' campaign celebrates women who have made a positive impact on their friends, family and community," said Lela Rose, American Fashion Designer and spokesperson for the campaign.  "My work celebrates the essence of being a woman through design that is feminine and approachable. I truly enjoy helping the woman who wears my designs to look her best while she does the things that matter to her the most."  Rose also shares that she has received BOTOX® Cosmetic treatments from a physician for nearly a decade.

"In 2002, an advertisement for BOTOX® Cosmetic first appeared in PEOPLE® Magazine's World Most Beautiful issue," said Colleen McKenna, Senior Marketing Director, Allergan Medical.  "Over the past decade, approximately 11 million BOTOX® Cosmetic treatments have been administered and millions of women have received real, noticeable results.  We are celebrating this milestone by kicking off our 'Women Just Like You' campaign in an ad in the 2012 World's Most Beautiful issue of PEOPLE® magazine on newsstands next week."

Five "Women Just Like You" will be selected by representatives of the PEOPLE® magazine marketing team and will win a trip for a photo shoot where they will be styled by Lela Rose and have a professional hair and make-up team prepare them for a photo shoot with photographer Dorian Caster, whose work has appeared in PEOPLE® magazine.  Their photos and stories will appear in a "Women Just Like You" ad in the "Best & Worst Dressed" issue of PEOPLE® magazine available on newsstands September 14, 2012.

"Women Just Like You" Contest Terms

Contest begins at 12:00:01 a.m. EST 4/19/12 and ends at 11:59:59 p.m. EST 6/8/12. Open to legal residents of the 50 United States and the District of Columbia who are 18 years of age or older (19 if AL or NE, 21 if MS) at time of entry. Void outside the United States, elsewhere and where prohibited by law. For full contest rules and instructions on how to enter, go to www.WomenJustLikeYou.com. There is no requirement for anyone to have received BOTOX® Cosmetic treatment in order to be eligible to enter this contest.

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

Indication
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in people 18 to 65 years of age for a short period of time (temporary).

IMPORTANT SAFETY INFORMATION

BOTOX® Cosmetic may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

• Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of
  life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months
  
  
• Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice (dysphonia), trouble saying words clearly (dysarthria), loss of bladder control, trouble breathing, trouble swallowing. If this happens, do not drive a car, operate machinery, or do other dangerous activities

The dose of BOTOX® Cosmetic is not the same as, or comparable to, another botulinum toxin product. There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines.

Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Tell your doctor or get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

Do not take BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.

Tell your doctor about all your muscle or nerve conditions, such as amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including severe dysphagia (difficulty swallowing) and respiratory compromise (difficulty breathing) from typical doses of BOTOX® Cosmetic.

Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; weakness of forehead muscles, such as trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to breast-feed (it is not known if BOTOX® Cosmetic passes into breast milk).

Human albumin and spread of viral diseases. BOTOX® Cosmetic contains albumin, a protein component of human blood. The potential risk of spreading viral diseases [eg Creutzfeldt-Jakob Disease (CJD)] via human serum albumin is extremely rare. No cases of viral diseases or CJD have ever been reported in association with human serum albumin.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal products. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.

Especially tell your doctor if you: have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin, such as Myobloc®, Dysport®, or Xeomin® in the past (be sure your doctor knows exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; or take a sleep medicine.

Other side effects of BOTOX® Cosmetic include: dry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, and dry eyes.

For more information refer to the Medication Guide or talk with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide.

About Allergan, Inc.

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 10,000 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work.

Forward-Looking Statements

This press release contains "forward-looking statements," including the statements by Ms. McKenna and Ms. Rose, and other statements regarding the safety, effectiveness and adverse events associated with BOTOX® Cosmetic.

These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, the uncertainties associated with the litigation and appeal process; general industry and pharmaceutical market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new pharmaceutical products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing a new product; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Additional information concerning the above-referenced risk factors and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2011 Annual Report on Form 10-K. Copies of Allergan's press releases and additional information about Allergan are available at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 714-246-4636.

© 2012 Allergan, Inc. Irvine, CA 92612. ® and ™ marks owned by Allergan, Inc. APC24VB12

Dysport® is a registered trademark of Ipsen Biopharm Limited
Myobloc® is a registered trademark of Solstice Neurosciences, Inc
Xeomin® is a registered trademark of Merz Pharma GmbH & Co.

SOURCE Allergan, Inc.